What is the stage of a 4 by 4 cm squamous cell carcinoma on the foot with inguinofemoral (groin area) lymphadenopathy (enlarged lymph nodes)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Staging of Squamous Cell Carcinoma of the Foot with Inguinofemoral Lymphadenopathy

This 4 cm squamous cell carcinoma of the foot with inguinofemoral lymphadenopathy requires pathologic confirmation of nodal involvement, but if confirmed positive, represents at minimum Stage III disease (regional lymph node metastasis).

Critical Staging Requirement

The presence of inguinofemoral lymphadenopathy does not automatically confirm metastatic disease, as enlarged lymph nodes can be reactive from chronic inflammation or infection 1. Ultrasound-guided fine needle aspiration (FNA) of the enlarged inguinal lymph nodes must be performed immediately to determine if the lymphadenopathy represents metastatic SCC 1. If FNA is inconclusive despite repeated attempts, surgical biopsy is required 1.

Staging Based on Nodal Status

If Lymph Nodes Are Positive for Metastatic SCC:

  • The tumor is classified as Stage III (T2N1M0 or higher) based on the 4 cm primary tumor size and confirmed regional lymph node involvement 2
  • The 4 cm tumor size alone places this in the T2 category (≥2 cm but <5 cm) 2
  • Regional lymph node involvement automatically elevates staging to at least Stage III regardless of primary tumor characteristics 1

If Lymph Nodes Are Negative for Metastatic SCC:

  • The tumor would be classified as Stage II (T2N0M0) based solely on the 4 cm primary tumor size without nodal involvement 2
  • However, this 4 cm tumor still requires complete staging workup given its size 1

Additional Staging Workup Required

Given the 4 cm tumor size, comprehensive staging must include 1, 2:

  • FDG-PET with CT scanning to evaluate for systemic and lymph node metastases (preferred modality) 1
  • If PET unavailable, CT or MRI of chest, abdomen, and pelvis to identify systemic or additional lymph node metastases 1
  • MRI of the foot to assess tumor extent and involvement of underlying structures (tendons, nerves, vessels, bone) given the anatomically complex location 1, 2

Important Staging Pitfalls

Do not assume clinically palpable lymph nodes are metastatic without pathologic confirmation - reactive lymphadenopathy is common and can mimic metastatic disease 1. Conversely, up to 25% of clinically negative lymph nodes may harbor micrometastases, emphasizing the critical importance of appropriate nodal evaluation 3.

The foot location is generally considered lower risk for metastasis compared to other anatomic sites, but the 4 cm size (≥2 cm) and presence of lymphadenopathy elevate this patient's risk profile substantially 2, 4, 5. Inadequate initial evaluation and treatment of foot SCC is common and leads to more aggressive definitive treatment requirements 4, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnostic Workup and Management of Squamous Cell Carcinoma of the Upper Extremity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Swollen Lymph Nodes in the Groin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Squamous cell carcinoma of the foot.

Foot & ankle international, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.